Where the Money Goes
You Power Cures
Obliteride funding matters at Fred Hutch — and our generous sponsors ensure that 100% of every dollar you raise goes right to work. In the last 10 years, we’ve fueled new approaches for breast, colon, pancreatic and prostate cancer. Advanced new breakthroughs in immunotherapy and data science. Supported community partnerships to improve health. Sparked urgently needed leadership in the response to COVID-19 and other infectious diseases. And helped Fred Hutch attract the world’s top researchers and nurture their most innovative work.
Our 2022 Funded Researchers
When you Obliteride, every dollar you raise goes directly to work. Meet the Fred Hutch scientists and research you support.
Learning how cells fix their broken DNA to understand cancer origins and inform new therapies.
Understanding our immune response to new and evolving viruses to improve treatments for current and emerging threats.
Developing therapies that optimize the cancer-fighting power of immune T cells while reducing side effects.
Studying how a type of bacteria leads to aggressive colorectal cancer to better prevent and treat it.
Improving screening by identifying genetic and other risk factors for prostate cancer in diverse populations.
Learning how immune T cells behave during and after treatment to improve immune-based therapies for children.
Refining blood stem cell transplantation and testing it to treat severe autoimmune diseases.
Researching mosquito- and tick-borne flaviviruses, including dengue and Zika, that threaten people worldwide.
Linking cellular changes to different prostate tumor pathologies to enhance diagnosis.
Illuminating the role of glia, which form one-half of our brain cells, in Alzheimer’s and autism.
Nasa Sinnott-Armstrong, PhD
Distilling complex genetic and environmental factors to better predict disease risk.
Uncovering how blood stem cells repopulate the bone marrow after radiation and transplant.
Improving stem cell transplantation and follow-up to catch relapse early.
Designing new immunotherapies that harness immune T cells to fight lung and skin cancers.
Harmonizing medical records and study data to recommend changes in disease diagnosis and public health measures.
A Decade of Discovery (And Counting)
Since 2013, Obliteride funding has supported more than 200 projects and more than 85 world-leading researchers — kickstarting a wheel of innovation that leads to even more discoveries over time. Here are three examples:
In 2017, we supported Dr. Roland Strong to improve cancer treatment by helping create a tool that identifies “targets” present in cancer cells, but not healthy cells.
Dr. Aude Chapuis, holder of the John C. and Karyl Kay Hughes Endowed Chair, is not building on this work: retraining the body’s own immune cells to recognize targets and attack cancers.
With Obliteride funding, Dr. Jen Adair holder of the Fleischauer Family Endowed Chair in Gene Therapy Translation developed a groundbreaking technology to make gene therapies for cancer more accessible worldwide.
Dr. Hootie Warren continues to help improve treatment around the world, especially in communities with limited access to care.
With early funding from Obliteride, Dr. Johanna Lampe identified nutrients associated with cancer risk, unlocking new insights into diet and risk reduction.
Now, Dr. Heather Greenlee is continuing to improve health and nutrition. Her website, Cook for Your Life, provides science-based recipes to reduce risk, address challenges during treatment, and more.